The Golden Era of PE Trials: PRAGUE-26

Show notes

This episode breaks down PRAGUE-26, a 558-patient NEJM randomized trial from 11 Czech centers testing whether low-dose thrombolysis through cheap generic infusion catheters beats anticoagulation alone, with expert commentary throughout from Dr. Jay Giri of Penn Medicine.

• The Protocol: Standard 4 French infusion catheters, no ultrasound facilitation, alteplase capped at 20 mg over a mean infusion of 9.3 hours. Median time from randomization to lysis was 76 minutes.
• The Result: The 7-day composite of death, recurrent PE, or cardiorespiratory decompensation fell from 6.8% to 0.7%, with faster RV recovery and shorter ICU stays.
• What Drove It: Decompensation, not mortality. The endpoint included a NEWS score of 9 or higher, more sensitive than the vasopressor or arrest criteria used in PEITHO.
• The Bleeding Tradeoff: Major bleeding was neutral, but two intracranial hemorrhages occurred in the thrombolysis arm versus zero with anticoagulation.
• The Cost Argument, Examined: Generic catheters are cheaper to buy, but Dr. Giri notes that US reimbursement places EKOS cases in a different DRG that covers the catheter. This was also not a head-to-head test of ultrasound facilitation.
• Caveats: Open-label with an unblinded events committee, no screening logs, a single homogeneous population, and no one over 80.

Tune in to learn where this trial actually moves the needle, and where the enthusiasm outruns the data.

This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.

Kroupa J, Radvan M, Mrozek J, et al. Catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism. N Engl J Med. Published online August 31, 2026. doi:10.1056/NEJMoa2608012